Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2018-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to continue appointing an accounting firm for the 2018 fiscal year audit and internal control audit services. It includes details about the audit firm, fees, and independent directors' opinions. The document is short (633 characters) and serves as a formal announcement rather than the audit report itself. It does not contain actual financial statements or audit results. Therefore, it fits the category of Audit Report / Information (AR), which covers standalone audit reports and related announcements excluding full annual reports. FY 2017
2018-04-25 Chinese
2017年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2017年度内部控制评价报告' which translates to '2017 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2017, including financial and non-financial internal control defects, audit opinions, and the scope and standards of the internal control evaluation. The content is focused on internal control evaluation rather than a full annual report or audit report. It is a standalone report on internal control evaluation, which fits the category of Audit Report / Information (AR). The document length is 3761 characters, which is sufficient to contain substantive content rather than just an announcement. Therefore, the classification is AR with high confidence. FY 2017
2018-04-25 Chinese
2017年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2017 annual report summary of 马应龙药业集团股份有限公司, containing detailed financial data such as total assets, revenue, net profit, quarterly financial data, segment revenue and cost analysis, shareholder information, and management discussion. It includes audited financial figures and a mention of an unqualified audit opinion by 中审众环会计师事务所. The length is substantial (15,000 characters), and the content is comprehensive, covering company operations, financial performance, and shareholder structure. This matches the characteristics of an Annual Report (10-K) rather than a brief announcement or a regulatory filing. Therefore, the document is classified as an Annual Report (10-K). FY 2017
2018-04-25 Chinese
控股股东及其关联方占用资金情况的专项说明
Regulatory Filings
2018-04-25 Chinese
关于再次获得高新技术企业证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company 马应龙药业集团股份有限公司 regarding the receipt of a High-Tech Enterprise Certificate, which allows the company to enjoy preferential tax policies for three years. The document includes details about the certificate, its validity, and the impact on the company's tax rate. It is a regulatory announcement about a certification and its implications, not a financial report, earnings release, or management discussion. The document is short (641 characters) and serves as a formal notification to investors about a regulatory status update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-02-26 Chinese
关于股东股权解除质押暨继续质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the release and re-pledging of shares by a major shareholder (China Baoan Group) of the company. It details the number of shares involved, the pledge terms, and the shareholder's stake percentages. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, as it informs about changes in significant share ownership levels and pledging status. The document is short and focused solely on share pledge information, not a full report or announcement of a meeting or dividend.
2018-01-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.